Fulgent Genetics misses 2025 revenue targets amid legal scrutiny
Fulgent Genetics, Inc. has released its financial results for 2025, showing mixed performance. The company reported full-year revenue of around $322.7 million, but figures fell just below its own updated forecasts. Meanwhile, a law firm has launched an inquiry into potential securities law breaches by the firm. The company’s fourth-quarter revenue dropped compared to the previous quarter. This decline contributed to the annual total of $322.7 million, which missed the company’s revised guidance by a narrow margin.
Following the financial report, Lowey Dannenberg P.C. announced it was examining whether Fulgent Genetics, Inc. had violated securities laws. The investigation will focus on the accuracy of the company’s public statements and compliance with financial regulations.
The revenue shortfall and ongoing legal scrutiny may impact investor confidence. Fulgent Genetics, Inc. now faces questions over its financial reporting practices. The outcome of the investigation remains uncertain.
